Stem Cell Clinic

Human Embryonic Stem Cells (HESC) Market 2019 | Analyzing The Impact Followed By Restraints, Opportunities And Projected Developments | DataIntelo -…

By adminDecember 6, 2020Embryonic Stem Cells

DataIntelo, one of the worlds prominent market research firms has released a new report on Global Human Embryonic Stem Cells (HESC) Market. The report contains crucial insights on the market which will support the clients to make the right business decisions. This research will help both existing and new aspirants for Human Embryonic Stem Cells (HESC) market to figure out and study market needs, market size, and competition. The report talks about the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities, and the threats faced by key players.

The report also includes the impact of ongoing global crisis i.e. COVID-19 on the Human Embryonic Stem Cells (HESC) market and what the future holds for it. The published report is designed using a vigorous and thorough research methodology and DataIntelo is also known for its data accuracy and granular market reports.

You can buy the report @ https://dataintelo.com/checkout/?reportId=94347

A complete analysis of the competitive scenario of the Human Embryonic Stem Cells (HESC) market is depicted by the report. The report has a vast amount of data about the recent product and technological developments in the markets. It has a wide spectrum of analysis regarding the impact of these advancements on the markets future growth, wide-range of analysis of these extensions on the markets future growth.

Human Embryonic Stem Cells (HESC) market report tracks the data since 2015 and is one of the most detailed reports. It also contains data varying according to region and country. The insights in the report are easy to understand and include pictorial representations. These insights are also applicable in real-time scenarios.

Request Free Sample Report @ https://dataintelo.com/request-sample/?reportId=94347

Components such as market drivers, restraints, challenges, and opportunities for Human Embryonic Stem Cells (HESC) are explained in detail. Since the research team is tracking the data for the market from 2015, therefore any additional data requirement can be easily fulfilled.

Some of the prominent companies that are covered in this report:

ESI BIO Thermo Fisher BioTime MilliporeSigma BD Biosciences Astellas Institute of Regenerative Medicine Asterias Biotherapeutics Cell Cure Neurosciences PerkinElmer Takara Bio Cellular Dynamics International Reliance Life Sciences Research & Diagnostics Systems SABiosciences STEMCELL Technologies Stemina Biomarker Discovery Takara Bio TATAA Biocenter UK Stem Cell Bank ViaCyte Vitrolife

*Note: Additional companies can be included on request

The industry looks to be fairly competitive. To analyze any market with simplicity the market is fragmented into segments, such as its product type, application, technology, end-use industry, etc. Segmenting the market into smaller components helps in understanding the dynamics of the market with more clarity. Data is represented with the help of tables and figures that consist of a graphical representation of the numbers in the form of histograms, bar graphs, pie charts, etc. Another key component that is included in the report is the regional analysis to assess the global presence of the Human Embryonic Stem Cells (HESC) market.

Following is the gist of segmentation:

By Application:

Research Clinical Trials Others

By Type:

Totipotent Stem Cells Pluripotent Stem Cells Unipotent Stem Cells

By Geographical Regions

Asia Pacific: China, Japan, India, and Rest of Asia Pacific Europe: Germany, the UK, France, and Rest of Europe North America: The US, Mexico, and Canada Latin America: Brazil and Rest of Latin America Middle East & Africa: GCC Countries and Rest of Middle East & Africa

You can also go for a yearly subscription of all the updates on the Human Embryonic Stem Cells (HESC) market.

Reasons you should buy this report:

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Human Embryonic Stem Cells (HESC) Market Overview

Human Embryonic Stem Cells (HESC) Supply Chain Analysis

Human Embryonic Stem Cells (HESC) Pricing Analysis

Global Human Embryonic Stem Cells (HESC) Market Analysis and Forecast by Type

Global Human Embryonic Stem Cells (HESC) Market Analysis and Forecast by Application

Global Human Embryonic Stem Cells (HESC) Market Analysis and Forecast by Sales Channel

Global Human Embryonic Stem Cells (HESC) Market Analysis and Forecast by Region

North America Human Embryonic Stem Cells (HESC) Market Analysis and Forecast

Latin America Human Embryonic Stem Cells (HESC) Market Analysis and Forecast

Europe Human Embryonic Stem Cells (HESC) Market Analysis and Forecast

Asia Pacific Human Embryonic Stem Cells (HESC) Market Analysis and Forecast

Middle East & Africa Human Embryonic Stem Cells (HESC) Market Analysis and Forecast

Competition Landscape

If you have any questions on this report, please reach out to us @ https://dataintelo.com/enquiry-before-buying/?reportId=94347

About DataIntelo:

DataIntelo has a vast experience in designing tailored market research reports in various industry verticals. We also have an urge to provide complete client satisfaction. We cover in-depth market analysis, which consists of producing lucrative business strategies for the new entrants and the emerging players of the market. We make sure that each report goes through intensive primary, secondary research, interviews, and consumer surveys before final dispatch. Our company provides market threat analysis, market opportunity analysis, and deep insights into the current market scenario.

We invest in our analysts to ensure that we have a full roster of experience and expertise in any field we cover. Our team members are selected for stellar academic records, specializations in technical fields, and exceptional analytical and communication skills. We also offer ongoing training and knowledge sharing to keep our analysts tapped into industry best practices and loaded with information.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

View post:
Human Embryonic Stem Cells (HESC) Market 2019 | Analyzing The Impact Followed By Restraints, Opportunities And Projected Developments | DataIntelo -...

Stem Cell Market Technology 2021 and Application, Segmentation by Leading Global Players, Market Status by Share and Size Forecast to 2024 – The…

By adminDecember 6, 2020Embryonic Stem Cells

International Stem Cell Corporation

Key Market Trends:

Oncology Disorders Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period

Cancer has a major impact on society in the United States and across the world. As per the estimation of National Cancer Institute, in 2018, 1,735,350 new cases of cancer were anticipated to get diagnosed in the United States, and 609,640 deaths were expected from the disease. This increasing medical burden is due to population growth. Bone marrow transplant or stem cell transplant is a treatment for some types of cancers, like leukemia, multiple myeloma, multiple myeloma, neuroblastoma, or some types of lymphoma.

Embryonic stem cells (ESC) are the major source of stem cells for therapeutic purposes, due to their higher totipotency and indefinite lifespan, as compared to adult stem cells with lower totipotency and restricted lifespan. However, the use of ESCs for research and therapeutic purposes is restricted and prohibited in many countries throughout the world, due to some ethical constraints. Scientists from the University of California, Irvine, created the stem cell-based approach to kill cancerous tissue while preventing some toxic side effects of chemotherapy by treating the disease in a more localized way.

Although the market shows positive growth, due to the growing focus of stem cell-based research that can further strengthen the clinical application, its expensive nature for stem cell therapy may still hamper its growth.

North America Captured The Largest Market Share and is Expected to Retain its Dominance

North America dominated the overall stem cell market with the United States contributing to the largest share in the market. In 2014, the Sanford Stem Cell Clinical Center at the University of California, San Diego (UCSD) Health System, announced the launch of a clinical trial, in order to assess the safety of neural stem cell-based therapy in patients with chronic spinal cord injury. Researchers hoped that the transplanted stem cells may develop into new neurons that could replace severed or lost nerve connections, and restore at least some motor and sensory functions. Such numerous stem cell studies across the United States have helped in the growth of the stem cell market.

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999718

Market Overview:

Report Highlights:

Scope of the Report:

The scope of this market is limited to tracking the stem cell market. As per the scope of this report, stem cells are biological cells that can differentiate into other types of cells. Also, various types of stem cells are used for therapeutic purposes.

Competitive Landscape:

Most of the companies present in the market are efficient at the technological front, but require significant support for enhancing their services and expanding their businesses. Thus, mergers and acquisitions offer significant opportunities to gain the attention of a large number of providers across developed regions.

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/13999718

Detailed TOC of Stem Cell Market Report 2024:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Increased Awareness about Umbilical Stem Cell 4.2.2 Increase in the Approval for Clinical Trials in Stem Cell Research 4.2.3 Growing Demand for Regenerative Treatment Option 4.2.4 Rising R&D Initiatives to Develop Therapeutic Options for Chronic Diseases 4.3 Market Restraints 4.3.1 Expensive Procedures 4.3.2 Regulatory Complications 4.3.3 Ethical and Moral Framework 4.4 Industry Attractiveness- Porters Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Product Type 5.1.1 Adult Stem Cell 5.1.2 Human Embryonic Cell 5.1.3 Pluripotent Stem Cell 5.1.4 Other Product Types 5.2 By Therapeutic Application 5.2.1 Neurological Disorders 5.2.2 Orthopedic Treatments 5.2.3 Oncology Disorders 5.2.4 Diabetes 5.2.5 Injuries and Wounds 5.2.6 Cardiovascular Disorders 5.2.7 Other Therapeutic Applications 5.3 By Treatment Type 5.3.1 Allogeneic Stem Cell Therapy 5.3.2 Auto logic Stem Cell Therapy 5.3.3 Syngeneic Stem Cell Therapy 5.4 By Banking Service and Technology 5.4.1 Stem Cell Acquisition and Testing 5.4.2 Cell Production 5.4.3 Expansion 5.4.4 Sub-culture 5.4.5 Cryopreservation 5.5 By Type of Banking 5.5.1 Public 5.5.2 Private 5.6 Geography 5.6.1 North America 5.6.1.1 US 5.6.1.2 Canada 5.6.1.3 Mexico 5.6.2 Europe 5.6.2.1 UK 5.6.2.2 Germany 5.6.2.3 France 5.6.2.4 Italy 5.6.2.5 Spain 5.6.2.6 Rest of Europe 5.6.3 Asia-Pacific 5.6.3.1 China 5.6.3.2 Japan 5.6.3.3 India 5.6.3.4 Australia 5.6.3.5 South Korea 5.6.3.6 Rest of Asia-Pacific 5.6.4 Middle East & Africa 5.6.4.1 GCC 5.6.4.2 South Africa 5.6.4.3 Rest of Middle East & Africa 5.6.5 South America 5.6.5.1 Brazil 5.6.5.2 Argentina 5.6.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Osiris Therapeutics Inc. 6.1.2 Pluristem Therapeutics Inc. 6.1.3 Thermo Fisher Scientific 6.1.4 Qiagen NV 6.1.5 Sigma Aldrich Corporation 6.1.6 Becton, Dickinson and Company 6.1.7 Stem Cell Technologies Inc. 6.1.8 AllCells LLC 6.1.9 Miltenyi Biotec 6.1.10 International Stem Cell Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Quick Coupling Market Size Analysis by Recent and Upcoming Trends 2020 | CAGR Status, Business Growth Demand and Share by Regions Forecast to 2026

Technical Grade Synthetic Camphor Market Size Analysis by Business Revenue Estimation 2020 | Industry Share, Product Overview, Growth Opportunities by Top Manufacturers Forecast to 2026

Hemorrhoid Treatment Instrument Market Size COVID-19 Impact on Industry Growth, Demand Status, New Technology, and Share Analysis with Business Opportunities Forecast to 2026

SD-WAN (Software-Defined Wide Area Network) Market: Business Growth Factors 2020 | Latest Opportunities, Technological Advancements, COVID-19 Impact on Industry Size and Share Forecast to 2025

Food Preservatives Market Size with Growth Status 2020 | Share and Gross Margin Analysis with COVID-19 Impact, Top Companies, Revenue, Business Development Plans Forecast to 2026

Soundproof Ventilator Market Share 2020 Global Manufacturers with Regional Analysis, Manufacturing Size, Growth Insights, Key Opportunities till 2024 Industry Research.co

Inkjet Labelling System Market Growth Opportunities by Key Players 2020 | Evolving Technologies, Market Dynamics, Global Size, Industry Share Analysis till 2026 Report by Industry Research.co

Protective Clothing Fabrics Market Size 2020 Business Growth Rate with Revenue, Leading Players Updates, Share Trends, and Future Developments till 2024 Industry Research.co

Diamond Micro Powder Market Size and Share Forecast Analysis, Top Key Players, Latest Developments, Growth Factors till 2020 to 2024 | Research Report by Industry Research.co

Leather Printing Machines Market Size and Share Analysis by Global Future Growth Rate, Developments Status, Trends, Industry Players Forecast 2020 to 2026 | Industry Research.co

Polyester Fabrics Market Size and Share 2020 | Industry Growth Factors Analysis by Top Regions, Competitive Landscape, Future Prospects, and Segmentation Analysis Outlook by 2025

Environmental Disinfection Robot Market Size and Share 2020 | Industry Growth Factors Analysis by Top Regions, Competitive Landscape, Future Prospects, and Segmentation Analysis Outlook by 2025

Stem Cell Therapy Market Size, Opportunities, Dynamic, Outlook and Forecast To 2027 – Cheshire Media

By adminDecember 6, 2020Embryonic Stem Cells

Allosource

Impact of Covid-19 on this Market:

Stem Cell Therapy Market report analyses the impact of Coronavirus (COVID-19) on the Stem Cell Therapy industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Stem Cell Therapy market in 2020.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=33553

Market Segments and Sub-segments Covered in the Report are as per below:

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

This Market Study covers the Stem Cell Therapy Market Size across segments. It aims at estimating the market size and the growth potential of the market across segments by component, data type, deployment type, organization size, vertical, and region. This Stem Cell Therapy study also includes an in-depth competitive analysis of the key market players, along with their company profiles, key observations related to product and business offerings, recent developments, and key market strategies.

Request customization of the report @https://reportsglobe.com/need-customization/?rid=33553

Reason to purchase Stem Cell Therapy market report:

Finally, the Stem Cell Therapy Market Report is a credible source of market research that will accelerate your business exponentially. The report gives the most important regional framework conditions, economic situations with item value, advantage, limit, production, supply, demand, market development rate and number, etc. Stem Cell Therapy Industry Report Also includes a new SWOT review task, speculative test research, and corporate return on investment research.

To learn more about the report, visit @ https://reportsglobe.com/product/global-stem-cell-therapy-market/

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

Stem Cells Market will grow at CAGR of 8.61% by 2027 Cheshire Media – Cheshire Media

By adminDecember 6, 2020Embryonic Stem Cells

According to Precedence Research, The Global Stem Cells Market size will reach USD 17.79 bn by 2027, growing at a CAGR of 8.61% during the forecast period 2020-2027.

Precedence Research started a new study on the global Stem Cells market, providing forecast for the period 2020-2027. The study provides an analysis of the global Stem Cells industry for the period 2016-2027, wherein 2020 to 2027 is the forecast period and 2019 is considered as the base year.

The study also includes key indicator assessment to define the potential growth prospects of the global market, along with forecast statistics regarding the progress of the market based on value (US$ million) and volume (tons). In the Stem Cells market study, lucrative opportunities are seen for Stem Cells. The report enumerates valuable insights to enable readers to make winning business decisions for the future growth of their businesses. The report sheds light on the significant factors that are constantly shaping the growth of the market, untapped opportunities for manufacturers, trends and developments, and other insights across various key segments. Macroeconomic factors that are directly or indirectly affecting the growth of the market are also incorporated in the report.

Get Sample Copy of this Report with an overview of Findings https://www.precedenceresearch.com/sample/1118

Key Questions Answered

Key indicators associated with the Stem Cells market have been evaluated thoroughly in the report. The study highlights vital market dynamics such as key drivers, challenges, and trends, along with opportunities in the global market. A comprehensive study on the supply chain of the global market has also been encompassed in the report.

Other key aspects laid down in this market include pricing strategy of the leading market players. Furthermore, forecast factors and forecast scenario of the market have been encompassed in the report to understand future prospects of the market.

The report also renders imperative numbers such as historical and forecast size of various segments of this market.

Y-o-Y growth comparison, volume and revenue comparison, and market share comparison of various market segments have been delivered in the report. The Stem Cells market has been analyzed at both regional and country levels.

The research report provides an exhaustive evaluation on the structure of the market, in tandem with a dashboard view of all the leading companies profiled in the report. A company share analysis on this market players has also been presented in the report, apart from the footprint matrix on the profiled market players. The report depicts the presence of manufacturers by leveraging an intensity map. In this market report, readers can avail a detailed taxonomy along with a comprehensive analysis on the competitive landscape. The study profiles incumbent companies as well as new entrants in the market, wherein, new product innovations and strategic initiatives of these players have been detailed.

Get Customization on this Research [emailprotected]https://www.precedenceresearch.com/customization/1118

Competition Landscape

The report has engulfed a chapter on the global Stem Cells markets competitive landscape, which provides detailed analysis and insights on companies offering. Profiles of key companies, along with a strategic overview of their M&A and expansion plans across geographies, have been delivered in this chapter. This chapter is priceless for report readers, as its enables them in gauging their growth potential in the market and implement key strategies for extending their market reach. This chapter offers key recommendations for both new and existing market participants, enabling them to emerge sustainably and profitably. Intelligence on the market players has been delivered on the basis of their product overview, SWOT analysis, key developments, key financials and company overview. Occupancy of these market participants has been tracked by the report and portrayed via an intensity map.

Key Companies:

Various players operating in the global Stem Cells markets are

Market Segmentation as below:

By Product

By Application

By Technology

By Therapy

By Regional Outlook

Research Methodology

A realistic methodology, along with a holistic approach makes the base for incisive insights provided in this market for the study evaluation period. The report comprises of detailed information on the growth prospects of this industry, along with riveting insights into the forecast assessment of the market.

Extensive primary and secondary research have been employed to garner incisive insights into the forecast study of this market. The research report has undergone through a cross-validation by in-house professionals to make the Stem Cells market report one-of-its-kind, with the highest credibility.

The Final Report will cover the impact analysis of COVID-19.

Download Full Study [emailprotected]https://www.precedenceresearch.com/checkout/1118

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call:+1 774 402 6168

Email:[emailprotected]

Blog: precedenceresearchnews.wordpress.com

View post:
Stem Cells Market will grow at CAGR of 8.61% by 2027 Cheshire Media - Cheshire Media

Stem Cells Market is Expected to Thrive at Impressive CAGR by 2025 – The Haitian-Caribbean News Network

By adminDecember 5, 2020Adult Stem Cells

This report studies the Stem Cells market size (value and volume) by players, regions, product types and end industries, history data 2013-2017 and forecast data 2018-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

Request Sample copy of this report athttps://www.precisionbusinessinsights.com/request-sample?product_id=30511

Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types. Commonly, stem cells come from two main sources: Embryos formed during the blastocyst phase of embryological development (embryonic stem cells) and Adult tissue (adult stem cells).

Both types are generally characterized by their potency, or potential to differentiate into different cell types (such as skin, muscle, bone, etc.).

Stem Cells market, by technology, is Cell Acquisition, Cell Production, Cryopreservation, Expansion, and Sub-Culture. Stem Cell Therapy in China is not mature, so in this report we mainly cover Stem Cell Banking market.

RequestCustomization copy of this report athttps://www.precisionbusinessinsights.com/request-customisation?product_id=30511

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Stem Cells in these regions, from 2013 to 2025, covering

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include

CCBC

Vcanbio

Boyalife

Beikebiotech

By the product type, the market is primarily split into

Umbilical Cord Blood Stem Cell

Embryonic Stem Cell

Adult Stem Cell

Other

By the end users/application, this report covers the following segments

Diseases Therapy

Healthcare

We can also provide the customized separate regional or country-level reports, for the following regions:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

Japan

South Korea

Australia

Indonesia

Singapore

Malaysia

Philippines

Thailand

Vietnam

Rest of Asia-Pacific

Europe

Germany

France

Italy

Spain

Russia

Rest of Europe

Central & South America

Brazil

Rest of Central & South America

Middle East & Africa

GCC Countries

Turkey

Egypt

South Africa

Rest of Middle East & Africa

The study objectives of this report are:

To study and analyze the global Stem Cells market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.

To understand the structure of Stem Cells market by identifying its various subsegments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global Stem Cells manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Stem Cells with respect to individual growth trends, future prospects, and their contribution to the total market.

To project the value and volume of Stem Cells submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our team is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

[emailprotected]

PH +1-866-598-1553

Go here to see the original:
Stem Cells Market is Expected to Thrive at Impressive CAGR by 2025 - The Haitian-Caribbean News Network

Stem Cell Assay to Register Substantial Expansion by 2026| Merck, Thermo Fisher Scientific, GE Healthcare – The Haitian-Caribbean News Network

By adminDecember 5, 2020Adult Stem Cells

The global Stem Cell Assay market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Stem Cell Assay market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global Stem Cell Assay market. The authors of the report profile leading companies of the global Stem Cell Assay market, such as Merck, Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad Laboratories, Promega, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio-Techne, STEMCELL They provide details about important activities of leading players in the competitive landscape.

The report predicts the size of the global Stem Cell Assay market in terms of value and volume for the forecast period 2019-2026. As per the analysis provided in the report, the global Stem Cell Assay market is expected to rise at a CAGR of XX % between 2019 and 2026 to reach a valuation of US$ XX million/billion by the end of 2026. In 2018, the global Stem Cell Assay market attained a valuation of US$_ million/billion. The market researchers deeply analyze the global Stem Cell Assay industry landscape and the future prospects it is anticipated to create.

This publication includes key segmentations of the global Stem Cell Assay market on the basis of product, application, and geography (country/region). Each segment included in the report is studied in relation to different factors such as consumption, market share, value, growth rate, and production.

Get Sample Copy of This Report:https://www.qyresearch.com/sample-form/form/2321931/global-stem-cell-assay-market

The comparative results provided in the report allow readers to understand the difference between players and how they are competing against each other. The research study gives a detailed view of current and future trends and opportunities of the global Stem Cell Assay market. Market dynamics such as drivers and restraints are explained in the most detailed and easiest manner possible with the use of tables and graphs. Interested parties are expected to find important recommendations to improve their business in the global Stem Cell Assay market.

Readers can understand the overall profitability margin and sales volume of various products studied in the report. The report also provides the forecasted as well as historical annual growth rate and market share of the products offered in the global Stem Cell Assay market. The study on end-use application of products helps to understand the market growth of the products in terms of sales.

Global Stem Cell Assay Market by Product: , Adult Stem Cells, Human Embryonic Stem Cells (hESCs)

Global Stem Cell Assay Market by Application: , Regenerative Medicine, Drug Discovery & Development, Clinical Research

The report also focuses on the geographical analysis of the global Stem Cell Assay market, where important regions and countries are studied in great detail.

Global Stem Cell Assay Market by Geography:

Methodology

Our analysts have created the report with the use of advanced primary and secondary research methodologies.

As part of primary research, they have conducted interviews with important industry leaders and focused on market understanding and competitive analysis by reviewing relevant documents, press releases, annual reports, and key products.

For secondary research, they have taken into account the statistical data from agencies, trade associations, and government websites, internet sources, technical writings, and recent trade information.

Enquire For Customization in the Report:https://www.qyresearch.com/customize-request/form/2321931/global-stem-cell-assay-market

Key questions answered in the report:

Get Full Report in your Inbox within 24 Hours at USD(3350): https://www.qyresearch.com/settlement/pre/6f72e898951bf47588dbbb264286a85a,0,1,global-stem-cell-assay-market

Table Of Contents:

1 Market Overview of Stem Cell Assay 1.1 Stem Cell Assay Market Overview 1.1.1 Stem Cell Assay Product Scope 1.1.2 Market Status and Outlook 1.2 Global Stem Cell Assay Market Size Overview by Region 2015 VS 2020 VS 2026 1.3 Global Stem Cell Assay Market Size by Region (2015-2026) 1.4 Global Stem Cell Assay Historic Market Size by Region (2015-2020) 1.5 Global Stem Cell Assay Market Size Forecast by Region (2021-2026) 1.6 Key Regions, Stem Cell Assay Market Size YoY Growth (2015-2026) 1.6.1 North America Stem Cell Assay Market Size YoY Growth (2015-2026) 1.6.2 Europe Stem Cell Assay Market Size YoY Growth (2015-2026) 1.6.3 Asia-Pacific Stem Cell Assay Market Size YoY Growth (2015-2026) 1.6.4 Latin America Stem Cell Assay Market Size YoY Growth (2015-2026) 1.6.5 Middle East & Africa Stem Cell Assay Market Size YoY Growth (2015-2026) 2 Stem Cell Assay Market Overview by Type 2.1 Global Stem Cell Assay Market Size by Type: 2015 VS 2020 VS 2026 2.2 Global Stem Cell Assay Historic Market Size by Type (2015-2020) 2.3 Global Stem Cell Assay Forecasted Market Size by Type (2021-2026) 2.4 Adult Stem Cells 2.5 Human Embryonic Stem Cells (hESCs) 3 Stem Cell Assay Market Overview by Application 3.1 Global Stem Cell Assay Market Size by Application: 2015 VS 2020 VS 2026 3.2 Global Stem Cell Assay Historic Market Size by Application (2015-2020) 3.3 Global Stem Cell Assay Forecasted Market Size by Application (2021-2026) 3.4 Regenerative Medicine 3.5 Drug Discovery & Development 3.6 Clinical Research 4 Global Stem Cell Assay Competition Analysis by Players 4.1 Global Stem Cell Assay Market Size by Players (2015-2020) 4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Stem Cell Assay as of 2019) 4.3 Date of Key Manufacturers Enter into Stem Cell Assay Market 4.4 Global Top Players Stem Cell Assay Headquarters and Area Served 4.5 Key Players Stem Cell Assay Product Solution and Service 4.6 Competitive Status 4.6.1 Stem Cell Assay Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data 5.1 Merck 5.1.1 Merck Profile 5.1.2 Merck Main Business 5.1.3 Merck Stem Cell Assay Products, Services and Solutions 5.1.4 Merck Stem Cell Assay Revenue (US$ Million) & (2015-2020) 5.1.5 Merck Recent Developments 5.2 Thermo Fisher Scientific 5.2.1 Thermo Fisher Scientific Profile 5.2.2 Thermo Fisher Scientific Main Business 5.2.3 Thermo Fisher Scientific Stem Cell Assay Products, Services and Solutions 5.2.4 Thermo Fisher Scientific Stem Cell Assay Revenue (US$ Million) & (2015-2020) 5.2.5 Thermo Fisher Scientific Recent Developments 5.3 GE Healthcare 5.5.1 GE Healthcare Profile 5.3.2 GE Healthcare Main Business 5.3.3 GE Healthcare Stem Cell Assay Products, Services and Solutions 5.3.4 GE Healthcare Stem Cell Assay Revenue (US$ Million) & (2015-2020) 5.3.5 Agilent Technologies Recent Developments 5.4 Agilent Technologies 5.4.1 Agilent Technologies Profile 5.4.2 Agilent Technologies Main Business 5.4.3 Agilent Technologies Stem Cell Assay Products, Services and Solutions 5.4.4 Agilent Technologies Stem Cell Assay Revenue (US$ Million) & (2015-2020) 5.4.5 Agilent Technologies Recent Developments 5.5 Bio-Rad Laboratories 5.5.1 Bio-Rad Laboratories Profile 5.5.2 Bio-Rad Laboratories Main Business 5.5.3 Bio-Rad Laboratories Stem Cell Assay Products, Services and Solutions 5.5.4 Bio-Rad Laboratories Stem Cell Assay Revenue (US$ Million) & (2015-2020) 5.5.5 Bio-Rad Laboratories Recent Developments 5.6 Promega 5.6.1 Promega Profile 5.6.2 Promega Main Business 5.6.3 Promega Stem Cell Assay Products, Services and Solutions 5.6.4 Promega Stem Cell Assay Revenue (US$ Million) & (2015-2020) 5.6.5 Promega Recent Developments 5.7 Cell Biolabs 5.7.1 Cell Biolabs Profile 5.7.2 Cell Biolabs Main Business 5.7.3 Cell Biolabs Stem Cell Assay Products, Services and Solutions 5.7.4 Cell Biolabs Stem Cell Assay Revenue (US$ Million) & (2015-2020) 5.7.5 Cell Biolabs Recent Developments 5.8 PerkinElmer 5.8.1 PerkinElmer Profile 5.8.2 PerkinElmer Main Business 5.8.3 PerkinElmer Stem Cell Assay Products, Services and Solutions 5.8.4 PerkinElmer Stem Cell Assay Revenue (US$ Million) & (2015-2020) 5.8.5 PerkinElmer Recent Developments 5.9 Miltenyi Biotec 5.9.1 Miltenyi Biotec Profile 5.9.2 Miltenyi Biotec Main Business 5.9.3 Miltenyi Biotec Stem Cell Assay Products, Services and Solutions 5.9.4 Miltenyi Biotec Stem Cell Assay Revenue (US$ Million) & (2015-2020) 5.9.5 Miltenyi Biotec Recent Developments 5.10 HemoGenix 5.10.1 HemoGenix Profile 5.10.2 HemoGenix Main Business 5.10.3 HemoGenix Stem Cell Assay Products, Services and Solutions 5.10.4 HemoGenix Stem Cell Assay Revenue (US$ Million) & (2015-2020) 5.10.5 HemoGenix Recent Developments 5.11 Bio-Techne 5.11.1 Bio-Techne Profile 5.11.2 Bio-Techne Main Business 5.11.3 Bio-Techne Stem Cell Assay Products, Services and Solutions 5.11.4 Bio-Techne Stem Cell Assay Revenue (US$ Million) & (2015-2020) 5.11.5 Bio-Techne Recent Developments 5.12 STEMCELL 5.12.1 STEMCELL Profile 5.12.2 STEMCELL Main Business 5.12.3 STEMCELL Stem Cell Assay Products, Services and Solutions 5.12.4 STEMCELL Stem Cell Assay Revenue (US$ Million) & (2015-2020) 5.12.5 STEMCELL Recent Developments 6 North America 6.1 North America Stem Cell Assay Market Size by Country 6.2 United States 6.3 Canada 7 Europe 7.1 Europe Stem Cell Assay Market Size by Country 7.2 Germany 7.3 France 7.4 U.K. 7.5 Italy 7.6 Russia 7.7 Nordic 7.8 Rest of Europe 8 Asia-Pacific 8.1 Asia-Pacific Stem Cell Assay Market Size by Region 8.2 China 8.3 Japan 8.4 South Korea 8.5 Southeast Asia 8.6 India 8.7 Australia 8.8 Rest of Asia-Pacific 9 Latin America 9.1 Latin America Stem Cell Assay Market Size by Country 9.2 Mexico 9.3 Brazil 9.4 Rest of Latin America 10 Middle East & Africa 10.1 Middle East & Africa Stem Cell Assay Market Size by Country 10.2 Turkey 10.3 Saudi Arabia 10.4 UAE 10.5 Rest of Middle East & Africa 11 Stem Cell Assay Market Dynamics 11.1 Industry Trends 11.2 Market Drivers 11.3 Market Challenges 11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer 13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See original here:
Stem Cell Assay to Register Substantial Expansion by 2026| Merck, Thermo Fisher Scientific, GE Healthcare - The Haitian-Caribbean News Network

Cancer Stem Cell Therapy Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 – Cheshire Media

By adminDecember 5, 2020Stem Cell Clinic

DATAINTELO has published a research report on the Cancer Stem Cell Therapy market. The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the report. It provides an in-depth analysis of the market segments which include products, applications, and end-user applications.

This report also includes a complete analysis of industry players that cover their latest developments, product portfolio, pricing, mergers, acquisitions, and collaborations. Moreover, it provides crucial strategies that are helping them to expand their market share. The Global Cancer Stem Cell Therapy Market research report is prepared by implying robust research methodology and including Porters Five Forces analysis to provide the complex matrix of the market.

Get Free Sample Report + All Related Graphs & Charts: https://dataintelo.com/request-sample/?reportId=117056

Key Highlights of the Report

Complete Purchase of Latest Version Global Cancer Stem Cell Therapy Market Study with COVID-19 Impact Analysis: https://dataintelo.com/checkout/?reportId=117056

Market Segmentation Covered in the report.

By Type

Autologous Stem Cell Transplants Allogeneic Stem Cell Transplants Syngeneic Stem Cell Transplants Other

The market research report is classified into the types of products and is analyzed in a detailed manner. Moreover, it includes potential future products that are expected to open new market avenues and can change the dynamics of the market. Each product type is analyzed on the basis of their developments, growth, and threats in the different regions.

By Application

Hospital Clinic Medical Research Institution Other

This report covers all the applications of the afore-mentioned products and also provides information on the potential applications in the foreseeable future. The dedicated research team has to look into all possible parameters and analyzed the applications that drive the growth of the market.

By Region

North America (U.S., Canada, Mexico)

Asia Pacific (India, China, Japan, South Korea, ASEAN, Rest of Asia Pacific)

Europe (Italy, Germany, France, Spain, Central & Eastern Europe, Rest of Europe)

Middle East & Africa (GCC, Turkey, Rest of the Middle East & Africa)

South America (Brazil, Argentina, Rest of South America)

One country of interest can be added with no additional cost on the report. Moreover, if more than one needs to be added, the regional segment quote may vary. In this report, the questions such as which country/region is expected to witness a steep rise in CAGR & year-on-year (Y-o-Y) are also covered.

Ask for the discount @ https://dataintelo.com/ask-for-discount/?reportId=117056

Competitive Landscape

AVIVA BioSciences AdnaGen Advanced Cell Diagnostics Silicon Biosystems

Note: Additional companies can be profiled in the report.

Frequently asked questions (FAQs) about the report

1) Does the report cover COVID-19 impact and future market projections?

Yes. The market research report covers the detailed analysis of COVID-19 impact on the market. Our research team has been monitoring the market closely while it has been conducting interviews with the industry experts to get better insights on the present and future implications of the COVID-19 virus on the market.

The market report provides vital information on the strategies deployed by industry players during the COVID-19 crisis to maintain their position in the market. Along with this, it also shares crucial data on product developments due to the inevitable pandemic across the globe.

2) Can the report be customized according to the requirements?

Yes. The Cancer Stem Cell Therapy market report can be customized according to your needs. For instance, the company can be profiled you ask for while specific region/country analysis can be focused that meets your interests. You can talk to our research analyst about your exact requirements and DATAINTELO will accordingly tailor the required report.

3) Can we narrow the available business segments?

Yes, the market report can be further segmented on the basis of data availability and feasibility. We can provide a further breakdown in product types and applications (if applicable) by size, volume, or revenue. In the market segmentation part, the latest product developments and customer behavior insights are also included to give an in-depth analysis of the market.

Get on the call with our research analyst if you have any particular doubts before buying the report @ https://dataintelo.com/enquiry-before-buying/?reportId=117056

About US:

DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry.

Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

More here:
Cancer Stem Cell Therapy Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - Cheshire Media

Short Redhead Reel Reviews for the week of Dec. 4 – ECM Publishers

By adminDecember 5, 2020Stem Cell Clinic

Rating system: (4=Don't miss, 3=Good, 2=Worth a look, 1=Forget it)

http://www.shortredheadreelreviews.com

For more reviews, click here.

76 Days (NR) (4) [Subtitled] [Opens Dec. 4 in Virtual Cinema sponsored by MSP Film Society (for more information, log on to mspfilm.org) and available on various VOD platforms.] A captivating, gut-wrenching, heartbreaking, informative, critically acclaimed, candid, moving, 93-minute documentary that follows the dedicated, caring, hazmat-suit-wearing medical staff at four Chinese hospitals, including the Wuhan Red Cross Hospital, during the 76-day lockdown between Jan. 23 and April 4 in Wuhan, China, in 2020 and their diligent attempts to treat and save an eclectic group of patients (such as a dementia-afflicted grandfather and a couple waiting in quarantine waiting to hold their newborn girl nicknamed little penguin) struggling with COVID-19 during the global pandemic.

Ending Disease (NR) (4) [Available Dec. 4 on various VOD platforms.] Joe Gantzs engaging, powerful, educational, inspirational, insightful, moving, 185-minute, four-part documentary that examines the passage of Proposition 71 in 2004 in California in which citizens agreed to fund $3 billion for stem cell and regenerative therapy research and follows ten FDA-approved clinical trials and progress of patients, including 19-year-old basketball player Ryan Custer who is a quadriplegic after a devastating spinal cord injury, Steve Sharples who is dealing with brain cancer, Rosie who is going blind from retinitis pigmentosa, gay man Andrew Caldwell coping with HIV/AIDS, anxiety-prone Korean Aaron who contracted HIV from a blood transfusion, young girl Ava who had a bone marrow transplant for an immune deficiency disorder called bubble baby disease, mother Cheryl who suffers from aggressive lymphoma, and Lucas Linder who had a spinal cord injury, participating in groundbreaking, controversial, and promising stem cell, CAR T-cell, and antibody therapies to hopefully cure or improve their condition and consists of commentary by numerous medical personnel involved in the trials, including Dr. Benham Badie, California institute of regenerative medicine (CIRM) first director Robert Klein, Dr. Henry Klassen at USC in Irvine, Dr. Amrita Krishnan at City of Hope, Dr. Nitya Nathwani at City of Hope, City of Hope trial coordinator Teresa Kim, Dr. John Zaia at City of Hope, Dr. Christopher Dvorak at University of San Francisco, Dr. Shekar Kurpad at Froedstet Hospital in Milwaukee, Paula Cannon PhD at USC, Dr. Richard Fessler at Rush Medical Center in Chicago, clinical research coordinator at USC in Irvine, Dr. Jay Lalezari at Quest Clinic in San Francisco, Dr. Jeff Grijalva, Dr. Stephen Forman at City of Hope, Dr. Judith Shizuru at Stanford, stem cell research director Dr. Irv Weissman at Stanford, Dr. Mike McCune at the Bill and Melinda Gates Foundation, and 31-year cancer survivor Ellen who was the first person to receive stem cell therapy.

The Life Ahead (PG-13) (3.5) [Thematic content, drug material involving minors, some sexual material, and language.] [Netflix only] A somber, moving, well-acted, realistic, raw, down-to-earth, 94-minute remake of Moshe Mizrahis 1977 film and based on Romain Garys novel The Life Before Us in which a streetwise, angry, lonely, orphaned, 12-year-old, Senegalese Muslim immigrant (Ibrahima Gueye), who resorts to selling cocaine for a greedy drug dealer (Massimiliano Rossi), reluctantly agrees to live with an elderly, traumatized, PTSD-afflicted Auschwitz survivor and former prostitute (Sophia Loren) who cares for children (Babak Karimi, et al.) of prostitutes (Abril Zamora, et al.) in a small coastal town in Italy and finds a friendship they both desperately need.

Red Riding: 1974, Part 1 (NR) (2) [DVD and VOD only] A heavy Yorkshire accent and a convoluted plot hinder this dark, well-acted, slow-moving, factually inspired film noir, which is directed by Julian Jarrold and adapted from David Peace's bestselling crime novels and based on the Yorkshire ripper case, about an ambitious, idealistic crime journalist (Andrew Garfield) who suffers beating and after beating as he investigates the rape and brutal murder of a young girl in 1974 and stumbles on a corrupt police force (David Morrissey, John Henshaw, Warren Clarke, et al.) in Yorkshire and a greedy land developer (Sean Bean) while falling for the mother (Rebecca Hall) of one victim.

Red Riding: 1980, Part 2 (NR) (2.5) [DVD and VOD only] When a Manchester detective (Paddy Considine), who is cheating on his wife (Lesley Sharp) with a colleague (Maxine Peake), is assigned to head up a team (John Henshaw, Sean Harris, et al.) to investigate the alleged thirteenth victim of the Yorkshire killer in 1980 in this superbly acted, muddled, bleak, factually inspired film noir, which is directed by James Marsh and adapted from David Peace's bestselling crime novels and based on the Yorkshire ripper case, he uncovers a layer of corruption in the police force (David Morrissey, James Fox, Warren Clarke, et al.) and lie after lie in the case.

Red Riding: 1983, Part 3 (NR) (2.5) [DVD and VOD only] In this final trilogy installment, which is equally well acted but hard-to-follow, of the factually inspired, atmosphere-laden, slow-paced film noir, which was directed by Anand Tucker, a Yorkshire solicitor (Mark Addy) becomes convinced, and eventually convinces the shady police superintendent (David Morrissey), that the dimwitted prisoner (Daniel Mays) who they incarcerated six year earlier for the murder of a schoolgirl when he copped to the crime is actually innocent after another 10-year-old girl goes missing.

Sound of Metal (R) (3.5) [Language throughout and brief nude images.] [Available Dec. 6 available on Amazon Prime Video.] When a former heroin-addicted, heavy-metal drummer (Riz Ahmed) suddenly loses his hearing after nightly gigs and his girlfriend/musical partner (Olivia Cooke), whose widowed father (Mathieu Amalric) lives in Paris, becomes increasingly concerned in this touching, enlightening, realistic, thought-provoking, well-acted, 130-minute, 2019 film, he struggles to accept his situation, contemplates getting cochlear implants, and finally agrees to enter a deaf community after accepting help from a deaf veteran (Paul Ravi), who lost his hearing in Viet Nam, and an ASL teacher (Lauren Ridloff).

Wendy Schadewald is a Burnsville resident.

New Cedars-Sinai Biomanufacturing Center to Spur Cell Therapies – Newswise

By adminDecember 5, 2020Stell Cell Research

Newswise LOS ANGELES (Dec. 4, 2020) -- Cedars-Sinai has launched a center to manufacture the next generation of stem cell and gene therapies that will enable biomedical researchers, government medical programs, commercial entities and others to develop new biologic drugs and propel novel disease discoveries.

Biologic drugs are produced from living organisms or contain components of living organisms, such as cells, proteins or genes.

"TheCedars-Sinai Biomanufacturing Centerleverages our world-class stem-cell expertise, which already serves scores of clients, to provide a much-needed biomanufacturing facility in Southern California," saidClive Svendsen, PhD, executive director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute. "It is revolutionary by virtue of elevating regenerative medicine and its therapeutic possibilities to an entirely new level-repairing the human body."

Among the facility's initial clients is the Department of Defense, which has asked Cedars-Sinai scientists to manufacture banks of stem cells from multiple healthy volunteers for later use in repairing vascular injuries sustained by military personnel in combat.

The core technology of the Cedars-Sinai Biomanufacturing Center involves production of specialized cells known as induced pluripotent stem cells, or iPSCs. Scientists make iPSCs by genetically converting adult blood cells into cells that can self-renew indefinitely and differentiate into nearly any type of tissue. Each resulting cell carries the exact DNA of the person who donated the blood sample.

"IPSCs are powerful tools for understanding human disease and developing therapies," saidDhruv Sareen, PhD, executive director of the Biomanufacturing Center and director of the induced pluripotent stem cell facility at the Regenerative Medicine Institute. "These cells enable us to truly practiceprecision medicineby developing drug treatments tailored to the individual patient or groups of patients with similar genetic profiles."

The Biomanufacturing Center is designed to address a critical bottleneck in bringing cell- and gene-based therapies to the clinic. It will help relieve a nationwide shortage of facilities that can scale up production of cells for drug products that consistently meet current good manufacturing practice (cGMP) standards for strength, quality, and purity. These standards, set by the U.S. Food and Drug Administration, must be met when producing pharmaceuticals for use in humans.

To comply with the federal standards, the new Cedars-Sinai center features nine "clean rooms" that maintain rigorously aseptic conditions for handling of all biomaterials. These rooms are supported by staging areas, gowning rooms, quality control laboratories and storage rooms with ample freezers and liquid nitrogen tanks.

Other sections of the Biomanufacturing Center are devoted to research and production of iPSC cells, technology and development, training and collaboration laboratories, offices, and facilities maintenance equipment. Overall, the center occupies more than 28,000 square feet.

"Our expansive facilities provide complete, end-to-end support of biomedical research and development of cell therapies that are 'living medicines,'" said Sareen, assistant professor of Biomedical Sciences. "We enable our clients to explore and create new types of cells, use them to make discoveries about diseases and transform the resulting biomaterials into cGMP-compliant therapies for testing in clinical trials."

The recent grand opening of the Biomanufacturing Center, hosted on a virtual platform by Cedars-Sinai leadership, was attended by representatives of local and federal governments, biotechnology companies, funding organizations and other stakeholders. It was followed by another Cedars-Sinai virtual event, a "Symposium on Translational Medicine and Biomanufacturing," that drew world-renowned keynote speakers from academia and industry and hundreds of attendees to explore the latest developments in these fields.

"Our new Biomanufacturing Center reaffirms Cedars-Sinai's commitment to deliver the finest clinical care for our patients-and patients everywhere-by expanding the frontiers of medical science," said Svendsen, professor of Biomedical Sciences and Medicine.

Read more on the Cedars-Sinai Blog:What Are Induced Pluripotent Stem Cells?

More:
New Cedars-Sinai Biomanufacturing Center to Spur Cell Therapies - Newswise

Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting…

By adminDecember 5, 2020Stell Cell Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD). The data from this clinical trial could provide proof-of-concept for MGTA-145, in combination with plerixafor, as the preferred mobilization regimen for patients with SCD. bluebird bios experience with plerixafor as a mobilization agent in sickle cell disease aligns with Magentas combination therapy approach, utilizing MGTA-145 plus plerixafor with potential to achieve safe, rapid and reliable mobilization of sufficient quantities of high-quality stem cells to improve outcomes associated with stem cell transplantation. Under the collaboration, the stem cells will be fully characterized, and Magenta will undertake preclinical studies to evaluate the ability of these cells to be gene corrected and engrafted in mouse models. The companies will co-fund the clinical trial and Magenta will retain all rights to its product candidate.

We are excited to build upon our leading position in the field of ex-vivo gene therapy and the promising clinical data with LentiGlobin in SCD with a collaboration focused on achieving improved stem cell mobilization, said Dave Davidson, M.D., chief medical officer, bluebird bio. In this initial study, we hope to establish whether the combination of plerixafor with MGTA-145 can generate appropriate CD34+ stem cells with a single round of mobilization. If successful, we hope to evaluate this novel mobilization regimen with LentiGlobin to make another step forward in the treatment of patients with SCD.

Achieving reliable and rapid stem cell mobilization and a simplified collection process can ensure the entire patient experience is optimal with respect to therapeutic outcome. The incorporation of bluebird bios experience in this area of treatment will be immensely valuable in further developing MGTA-145 plus plerixafor to address the remaining unmet needs in gene therapy approaches for diseases like sickle cell disease, said John Davis Jr., M.D., M.P.H., M.S., Head of Research & Development and Chief Medical Officer, Magenta Therapeutics. We look forward to collaborating with bluebird bio to evaluate MGTA-145 as the preferred mobilization option for people with sickle cell disease.

SCD is a serious, progressive and debilitating genetic disease caused by a mutation in the -globin gene that leads to the production of abnormal sickle hemoglobin (HbS), causing red blood cells (RBCs) to become sickled and fragile, resulting in chronic hemolytic anemia, vasculopathy and painful vaso-occlusive events (VOEs). For adults and children living with SCD, this means unpredictable episodes of excruciating pain due to vaso-occlusion as well as other acute complicationssuch as acute chest syndrome (ACS), stroke, and infections, which can contribute to early mortality in these patients.

Currently available mobilization drugs, including granulocyte-colony stimulating factor (G-CSF), a commonly used mobilization agent administered over the course of five to seven days in other transplant settings, is not used in sickle cell disease because it can trigger vaso-occlusive crises and even death in adults and adolescents. Plerixafor is used to mobilize a patients stem cells for collection prior to transplant and while an available treatment option, multiple cycles of apheresis and collection may sometimes be required to generate sufficient stem cells for gene therapy. Magenta is developing MGTA-145, in combination with plerixafor, to be the preferred mobilization regimen for rapid and reliable mobilization and collection of hematopoietic stem cells (HSCs) to improve stem cell transplantation outcomes in multiple disease areas, including genetic diseases such as sickle cell disease, as well as blood cancers and autoimmune diseases.

About Magenta Therapeutics MGTA-145

MGTA-145, in combination with plerixafor, has demonstrated, in a recently completed Phase 1 study in healthy volunteers, it can rapidly and reliably mobilize high numbers of functional stem cells in a single day, without the need for G-CSF. MGTA-145 works in combination with plerixafor to harness a physiological mechanism of stem cell mobilization to rapidly and reliably mobilize HSCs for collection and transplant across multiple indications.

Additionally, as shown in preclinical studies, stem cells mobilized with MGTA-145 can be efficiently gene-modified and are able to engraft, potentially allowing for safer and more efficient mobilization for gene therapy approaches to treat sickle cell disease and other genetic diseases.

Magenta completed its Phase 1 trial of MGTA-145 in healthy volunteers, demonstrating MGTA-145 was well tolerated and enables same-day dosing, mobilization and simplified collection of sufficient stem cells for transplant, meeting all primary and secondary endpoints.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, were developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, were working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. Were putting our care and expertise to work across a spectrum of disorders: cerebral adrenoleukodystrophy, sickle cell disease, -thalassemia and multiple myeloma, using gene and cell therapy technologies including gene addition, and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

LentiGlobin and bluebird bio are trademarks of bluebird bio, Inc.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as may, will, could, should, expects, intends, plans, anticipates, believes, estimates, predicts, projects, seeks, endeavour, potential, continue or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption Risk Factors in Magentas Annual Report on Form 10-K filed on March 3, 2020, and in bluebird bios Annual Report on Form 10-K filed on February 18, 2020, as updated by each companys most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta and bluebird bio believe that the expectations reflected in the forward-looking statements are reasonable, neither Magenta nor bluebird bio can guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta or bluebird bio, nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. Neither Magenta nor bluebird undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Continue reading here:
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta's MGTA-145 for Mobilizing and Collecting...